Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Prescribing Pattern and Safety Analysis of Nonsteroidal Anti-inflammatory Drug and Gastro- Protective Agent following Reimbursement Guidelines Relaxation

요양급여심사기준 완화에 따른 비스테로이드성 항염제 및 위장관 보호제 처방 변화 및 안정성 분석

  • Received : 2017.10.11
  • Accepted : 2017.12.07
  • Published : 2017.12.29
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: The prevalence rate of osteoarthritis in Koreans aged 50 years or older is 14.3%, and the total amount of medical costs is more than KRW 1 trillion. Recently, the reimbursement guidelines for osteoarthritis treatment have changed. Methods: In this study, we sought to describe prescription patterns of nonsteroidal anti-inflammatory drugs (NSAIDs) and gastro-protective agent (GPA) and analyze the clinical and economic impacts of the new policy using the national health insurance claims data. The incidence of upper gastrointestinal adverse event by policy change was identified through the odds ratio, and changes in medicine and medical costs related to osteoarthritis through mean and median. Results: There were 204,552 patients before the reimbursement guidelines relaxation and 239,710 after it, a 17.2% rise. The prescription ratio was 3.3% for the patients prescribed with COX-2 selective NSAIDs alone and 1.3% for those with both COX-2 selective NSAIDs and GPA combination before the reimbursement guidelines relaxation. The reimbursement guidelines relaxation significantly increased their ratios to 6.9% and 2.8%, respectively. Gastrointestinal adverse events significantly reduced by 1.21%p after reimbursement guidelines relaxation. The average medicine cost per person increased significantly to KRW 140,291 from KRW 137,323 after the reimbursement guidelines relaxation, while the average medical cost per person slightly decreased from KRW 311,605 to KRW 310,755 after the relaxation, showing no meaningful difference. Conclusion: The reimbursement guidelines relaxation may influence on decreasing the upper gastrointestinal adverse event, increasing the medicine costs and maintaining the medical costs for osteoarthritis.

Keywords

References

  1. Lim HC. Osteoarthritis, degenerative arthritis. In; The Korean Orthopaedic Association, Orthopaedics, 7e: Choisineuihaksa, 2013:317-26.
  2. Lee CK. Rheumarthritis. In; Korean College of Rheumatology, KCR Textbook of Rheumatology, 1e: Koonja, 2014:275-314.
  3. Kim HR, Kim EJ. Prevalence of osteoarthritis and its affecting factors among a Korean population aged 50 and Over. J Korean Public Health Nurs 2013:27(1):27-39. https://doi.org/10.5932/JKPHN.2013.27.1.27
  4. Hochberg MC, Altman RD, April KT, et al. American college of rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012;64(4):465-74. https://doi.org/10.1002/acr.21596
  5. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee Osteoarthritis. Osteoarthritis Cartilage 2014;22:363-88. https://doi.org/10.1016/j.joca.2014.01.003
  6. Tannenbaum H, Bombardier C, Davis P, et al. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 2006;33(1):140-57.
  7. L MP. Rheumatologic disorder. In; Joseph TD, Robert LT, Gary CY et al, Pharmacotherapy: A Pathophysiologic Approach, 8e: McGraw-Hill Education, 2011:1559-632.
  8. Kujubu DA, Fletcher BS, Varnum BC, et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266:12866-72.
  9. O'Banion MK, Sadowski HB, Winn V, et al. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991;266:23261-7.
  10. Xie WL, Chipman JG, Robertson DL, et al. Expression of a mitogenresponsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 1991;88:2692-6. https://doi.org/10.1073/pnas.88.7.2692
  11. Song YJ, HA CW. The use of COX-2 selective nonsteroidal antiinflammatory drugs for the treatment of osteoarthritis. Knee Surgery & Related Reseach 2009;21(2):84-92.
  12. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284(10):1247-55. https://doi.org/10.1001/jama.284.10.1247
  13. Singh G, Fort JG, Goldstein JL,et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006;119(3):255-66. https://doi.org/10.1016/j.amjmed.2005.09.054
  14. Chan FK, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010;376(9736):173-9. https://doi.org/10.1016/S0140-6736(10)60673-3
  15. JA Kim, Kim LY. Introduction and utilization of Health Insurance Review and Assessment Service claim data for medical health research. Obstructive Lung Disease 2014;02(01):3-9.
  16. Park BJ, Jung JH, Park KD, et al. Study on Diagnosis Accuracy for Health Insurance Claims data in Korea, report to Health Insurance Review and Assessment Services. Medical School of Seoul National University. 2003.
  17. Lee JH, Lee YC, Jeon SW, et al. Guidelines of Prevention and Treatment for NSAID-related Peptic Ulcers. The Korean Journal of Gastroenterology 2009;54:309-17. https://doi.org/10.4166/kjg.2009.54.5.309
  18. Korean Knee Society Subcommittee on Osteoarthritis. Guidelines for the Treatment of Osteoarthritis of the Knee 2010;20(1):69-74.
  19. Neubert A, Verhamme K, Murray ML, et al. The prescribing of analgesics and non-steroidal anti-inflammatory drugs in paediatric primary care in the UK, Italy and the Netherlands. Pharmacological Research 2010;62(3):243-8. https://doi.org/10.1016/j.phrs.2010.04.006
  20. Chang CH, Chen HC, Lin JW, et al. Risk of hospitalization for upper gastrointestinal adverse events associated with nonsteroidal antiinflammatory drugs: a nationwide case-crossover study in Taiwan. Pharmacoepidemiology and drug safety 2011;20:763-71. https://doi.org/10.1002/pds.2140
  21. Cho JW, Lee ES, Shin WG. Evaluation of NSAID Usage and Appropriateness for Prevention of NSAID-Related Ulcer Complications. Korean J Clin Pharm 2012;22(3):211-9.
  22. Baek SH, Kim SY. Pharmacologic treatment of osteoarthritis. J Korean Public Heath Nurs 2013;56(12):1123-31.
  23. Weighted average price of drugs in 2011 2nd half. Available from http://www.hira.or.kr/dummy.do?pgmid=HIRAA030017000000&cmsurl=/ cms/medi_info/03/06/06/1211003_27001.html. Accessed Dec 6, 2016.
  24. Weighted average price of drugs in 2015. Available from http://www.hira.or.kr/dummy.do?pgmid=HIRAA030017000000&cmsurl=/ cms/medi_info/03/06/06/1345492_27001.html. Accessed Dec 6, 2016.
  25. Louder AM, Joshi AV, Ball AT, et al. Impact of celecoxib restrictions in medicare beneficiaries with arthritis. Am J Manag Care 2011;17(7):503-12.
  26. Quan S, Frolkis A, Milne K, et al. Upper-gastrointestinal bleeding secondary to peptic ulcer disease: Incidence and outcomes. World J Gastroenterol 2014;20(46):17568-77. https://doi.org/10.3748/wjg.v20.i46.17568

Cited by

  1. Association between hemoglobin variability and incidence of hypertension over 40 years: a Korean national cohort study vol.10, pp.None, 2017, https://doi.org/10.1038/s41598-020-69022-x
  2. Underutilization of gastrointestinal prophylaxis in high-risk chronic nonsteroidal anti-inflammatory drug users in Korea vol.43, pp.3, 2017, https://doi.org/10.1007/s11096-020-01176-0